Recombinant bispecific antibody binding to CD20 and CD95

A bispecific antibody, which comprises

• a) a Fab fragment comprising a first binding site for a first antigen and a hinge region which is modified to exchange one or more cysteine residues that would form interchain disulfide bonds;
• b) an scFv fragment comprising a second binding site for a second antigen;
• and
• c) a monomeric CH2 domain, wherein the CH2 domain is bound via its N-terminus to a) the Fab fragment, and via its C-terminus to b) the scFv fragment, wherein
• the first antigen is CD95 and the second antigen is CD20;
• or
• the first antigen is CD20 and the second antigen is CD95;
• wherein the binding site that binds CD20 comprises six complementarity determining regions of antibody variable domains VL-CDR1-3 and VH-CDR1-3), wherein
• i) VL-CDR1 comprises the amino acid sequence RASSSVSYM (SEQ ID NO:
• 12);
• ii) VL-CDR2 comprises the amino acid sequence APSNLAS (SEQ ID NO:
• 13);
• iii) VL-CDR3 comprises the amino acid sequence QQWSFNPPT (SEQ ID NO:
• 14);
• iv) VH-CDR1 comprises the amino acid sequence SYNMH (SEQ ID NO:
• 16);
• v) VH-CDR2 comprises the amino acid sequence AIYPGNGDTSYNQKFKG (SEQ ID NO:
• 17);
• and
• vi) VH-CDR3 comprises the amino acid sequence VVYYSNSYWYFDV (SEQ ID NO:
• 18);
• and wherein the binding site that binds CD95 comprises six complementarity determining regions of variable antibody domains (VL-CDR1-3 and VH-CDR1-3), wherein
• i) VL-CDR1 comprises the amino acid sequence RASESVEYYGTSLMQ (SEQ ID NO:
• 2);
• ii) VL-CDR2 comprises the amino acid sequence VASNVES (SEQ ID NO:
• 3);
• iii) VL-CDR3 comprises the amino acid sequence QQSTKVPWT (SEQ ID NO:
• 4);
• iv) VH-CDR1 comprises the amino acid sequence TNAMN (SEQ ID NO:
• 6);
• v) VH-CDR2 comprises the amino acid sequence RIRSKSNNYATYYAESVKD (SEQ ID NO:
• 7);
• and
• vi) VH-CDR3 comprises the amino acid sequence DGYY (SEQ ID NO:
• 8).